Active Biotech Stock: Alkermes’ Pipeline Development Impresses, Stock Rises Up
Alkermes (NASDAQ ALKS) is leaving no stone unturned to develop its pipeline successfully. The biopharmaceutical company’s pipeline expanded significantly following the purchase of the erstwhile Elan’s drug delivery unit. Elan was acquired by Perrigo Company (NASDAQ PRGO) last year. Important pipeline candidates at Alkermes include ALKS 5461 for treating patients suffering from major depressive disorder…
